Literature DB >> 33112391

Evolving Trends in Adult Heart Transplant With the 2018 Heart Allocation Policy Change.

Arman Kilic1, Michael A Mathier2, Gavin W Hickey2, Ibrahim Sultan1, Victor O Morell3, Suresh R Mulukutla2, Mary E Keebler2.   

Abstract

Importance: The US heart allocation policy was changed on October 18, 2018. The association of this change with recipient and donor selection and outcomes remains to be elucidated. Objective: To evaluate changes in patient characteristics, wait list outcomes, and posttransplant outcomes after the recent allocation policy change in heart transplant. Design, Setting, and Participants: In this cohort study, all 15 631 adults undergoing heart transplants, excluding multiorgan transplants, in the US as identified by the United Network for Organ Sharing multicenter, national registry were reviewed. Patients were stratified according to prepolicy change (October 1, 2015, to October 1, 2018) and postpolicy change (October 18, 2018 or after). Follow-up data were available through March 31, 2020. Exposures: Heart transplants after the policy change. Main Outcomes and Measures: Competing risk regression for wait list outcomes was performed. Posttransplant survival was compared using the Kaplan-Meier method, and risk adjustment was performed using multivariable Cox proportional hazards regression analysis.
Results: In this cohort study, of the 15 631 patients undergoing transplant, 10 671 (mean [SD] age, 53.1 [12.7] years; 7823 [73.3%] male) were wait listed before and 4960 (mean [SD] age, 52.7 [13.0] years; 3610 [72.8%] male) were wait listed after the policy change. Competing risk regression demonstrated reduced likelihood of mortality or deterioration (subhazard ratio [SHR], 0.60; 95% CI, 0.52-0.69; P < .001), increased likelihood of transplant (SHR, 1.38; 95% CI, 1.32-1.45; P < .001), and reduced likelihood of recovery (SHR, 0.54; 95% CI, 0.40-0.73; P < .001) for wait listed patients after the policy change. A total of 6078 patients underwent transplant before and 2801 after the policy change. Notable changes after the policy change included higher frequency of bridging with temporary mechanical circulatory support and lower frequency of bridging with durable left ventricular assist devices. Posttransplant survival was reduced after the policy change (1-year: 92.1% vs 87.5%; log-rank P < .001), a finding that persisted after risk adjustment (HR, 1.29; 95% CI, 1.07-1.55; P = .008). Conclusions and Relevance: Substantial changes have occurred in adult heart transplant in the US after the policy change in October 2018. Wait list outcomes have improved, although posttransplant survival has decreased. These data confirm findings from earlier preliminary analyses and demonstrate that these trends have persisted to 1-year follow-up, underscoring the importance of continued reevaluation of the new heart allocation policy.

Entities:  

Mesh:

Year:  2021        PMID: 33112391      PMCID: PMC7593876          DOI: 10.1001/jamacardio.2020.4909

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  13 in total

Review 1.  Critically appraising the 2018 United Network for Organ Sharing donor allocation policy: adding life boats or rearranging the deck chairs?

Authors:  Lauren K Truby; Maryjane Farr; Veli K Topkara
Journal:  Curr Opin Anaesthesiol       Date:  2022-02-01       Impact factor: 2.706

2.  Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System.

Authors:  Kevin J Clerkin; Oluwafeyijimi Salako; Justin A Fried; Jan M Griffin; Jayant Raikhelkar; Rashmi Jain; Susan Restaino; Paolo C Colombo; Koji Takeda; Maryjane A Farr; Gabriel Sayer; Nir Uriel; Veli K Topkara
Journal:  JACC Heart Fail       Date:  2021-11-10       Impact factor: 12.035

3.  Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.

Authors:  Brian Wayda; Alexander T Sandhu; Justin Parizo; Jeffrey J Teuteberg; Kiran K Khush
Journal:  J Heart Lung Transplant       Date:  2021-09-13       Impact factor: 10.247

4.  Foreword.

Authors: 
Journal:  Interv Cardiol       Date:  2022-06-29

5.  Relationships between 2018 UNOS heart policy and transplant outcomes in metropolitan, micropolitan, and rural settings.

Authors:  Khadijah Breathett; Shannon M Knapp; Daniel Addison; Amber Johnson; Rashmee U Shah; Kelsey Flint; Harriette G C Van Spall; Nancy K Sweitzer; Sula Mazimba
Journal:  J Heart Lung Transplant       Date:  2022-06-26       Impact factor: 13.569

6.  Between-center variation in high-priority listing status under the new heart allocation policy.

Authors:  Gege Ran; Kevin Chung; Allen S Anderson; Robert D Gibbons; Nikhil Narang; Matthew M Churpek; William F Parker
Journal:  Am J Transplant       Date:  2021-05-05       Impact factor: 8.086

7.  Improvements in Functional Status Among Survivors of Orthotopic Heart Transplantation Following High-risk Bridging Modalities.

Authors:  Lauren V Huckaby; Gavin Hickey; Ibrahim Sultan; Arman Kilic
Journal:  Transplantation       Date:  2021-09-01       Impact factor: 4.939

8.  An updated estimate of posttransplant survival after implementation of the new donor heart allocation policy.

Authors:  Kevin A Lazenby; Nikhil Narang; Kenley M Pelzer; Gege Ran; William F Parker
Journal:  Am J Transplant       Date:  2022-01-06       Impact factor: 9.369

Review 9.  Bridge to transplantation from mechanical circulatory support: a narrative review.

Authors:  Alice L Zhou; Eric W Etchill; Katherine A Giuliano; Benjamin L Shou; Kavita Sharma; Chun W Choi; Ahmet Kilic
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

10.  Heart transplantation strategies in arrhythmogenic right ventricular cardiomyopathy: a tertiary ARVC centre experience.

Authors:  Paul J Scheel; Katherine Giuliano; Crystal Tichnell; Cynthia James; Brittney Murray; Harikrishna Tandri; Debra Carter; Tracey Fehr; Priya Umapathi; Joban Vaishnav; Sabra C Lewsey; Steven Hsu; Hugh Calkins; Kavita Sharma; Chun Woo Choi; Nisha A Gilotra; Ahmet Kilic
Journal:  ESC Heart Fail       Date:  2021-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.